Current and Future Trends in MS Management: Near East Perspective
Multiple Sclerosis and Related Disorders
; Conference: Abstracts of The Seventh MENACTRIMS Congress. Intercontinental City Stars Hotel, 2023.
Article
in English
| EMBASE | ID: covidwho-2302932
ABSTRACT
Objective(s) The objectives were to provide an overview of the current practices of Near East (NE) healthcare practitioners (HCPs) by probing their prescribing decisions, to report the COVID-19 impacts on neurologists' prescribing habits, and to explore the future relevance of current medication used in MS management among other newcomers Material(s) and Method(s) A cross-sectional study was carried out using an online survey from April 27, 2022, to July 5, 2022. The questionnaire was designed with the input of five neurologists representing five NE countries (Iran, Iraq, Lebanon, Jordan & Palestine). They identified several factors that play a crucial role in the optimal care of MS patients. The link was shared among neurologists using snowball sampling Result(s) The survey included 98 neurologists from the included NE countries, the majority of whom had more than 15 years of experience in the field, and 39% were seeing more than 40 MS patients a month. Effectiveness and safety balance was the most important factor considered when selecting the MS treatment. In the treatment of mild to moderate RRMS in men, Interferon beta 1a SC, Fingolimod, and Glatiramer acetate were the most commonly recommended treatments. Dimethyl fumarate substituted fingolimod in female patients. According to 80.7% of participants, interferon beta 1a SC was the safest treatment for mild to moderate RRMS. Interferon beta 1a SC was preferred over other treatments for patients with mild to moderate MS and planning for pregnancy (56.6%) or breastfeeding (60.2%). Fingolimod was not a choice for these patients. Neurologists seemed to discuss the top three treatments of Natalizumab, Ocrelizumab, and Cladribine with patients with highly active MS. Conclusion(s) Most neurologists in the NE region followed MENACTRIMS recommendations for prescribing treatment. The treatment choice also depended on the availability of DMTs in the region. Regarding the use of upcoming DMTs such as Ofatumumab, Siponimod, Ozanimod, and BTK inhibitors, there is a clear need for real-world data, long-term extension studies, and comparative studies to support their efficacy and safety profiles in treating patients with MSCopyright © 2022
adult; breast feeding; clinical article; comparative effectiveness; comparative study; conference abstract; controlled study; coronavirus disease 2019; cross-sectional study; drug efficacy; drug safety; drug therapy; female; habit; health care personnel; human; Iran; Iraq; Jordan; Lebanon; male; neurologist; Palestine; pregnancy; prescription; questionnaire; relapsing remitting multiple sclerosis; substitution reaction; trend study; beta1a interferon; Bruton tyrosine kinase inhibitor; cladribine; fingolimod; glatiramer; natalizumab; ocrelizumab; ofatumumab; ozanimod; siponimod
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Multiple Sclerosis and Related Disorders
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS